ReNeuron will present new data relating to its CTX stem cell platform today at the European Society of Gene and Cell Therapies Annual Congress. The company has mentioned that the CTX stem cell line, which is currently being clinically evaluated for the treatment of stroke disability, can be reprogrammed to a pluripotent state.
Though in an early stage of development, successful implementation could be used to produce new conditionally immortalised allogeneic cell lines from any of the three germ layers: ectoderm, mesoderm and endoderm. The company is also focussing on developing new allogeneic cell lines, including NK and T-cells as potential therapeutic agents for third parties licensing.
Dr Randolph Corteling, RENE’s Head of Research, commented: “The possibility of generating an allogeneic source of haematopoietic stem cells from clinical-grade CTX cell line offers the prospect of a potential non-patient-specific alternative to those cancer immunotherapies in development that currently rely on the use of the patient’s own T-cells.”